MeiraGTx Holdings Current Ratio 2017-2021 | MGTX

MeiraGTx Holdings current ratio from 2017 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
MeiraGTx Holdings Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.21B $0.06B 3.62
2021-03-31 $0.23B $0.05B 4.30
2020-12-31 $0.27B $0.05B 5.03
2020-09-30 $0.22B $0.05B 4.68
2020-06-30 $0.24B $0.05B 5.03
2020-03-31 $0.25B $0.04B 5.83
2019-12-31 $0.27B $0.05B 5.47
2019-09-30 $0.27B $0.04B 6.90
2019-06-30 $0.21B $0.04B 5.22
2019-03-31 $0.23B $0.03B 6.96
2018-12-31 $0.08B $0.02B 4.82
2018-09-30 $0.09B $0.01B 10.76
2018-06-30 $0.10B $0.01B 11.84
2018-03-31 $0.04B $0.01B 2.59
2017-12-31 $0.01B $0.02B 0.54
2017-09-30 $0.00B 0.00
2017-06-30 $0.00B 0.00
2017-03-31 $0.00B 0.00
2016-12-31 $0.02B $0.01B 3.16
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.965B $0.016B
MeiraGTx Holdings plc focuses on operating as a holding company for MeiraGTx Limited which operates as a clinical stage gene therapy company. It develops novel gene therapy treatments for inherited and acquired disorders. The company's product pipeline consists of AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1, AAV-AQP1 and AAV-UPF1 which are in clinical stage. MeiraGTx Holdings plc is based in New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86